^
Association details:
| Biomarker: | FGFR2-CCDC6 fusion |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | Truseltiq (infigratinib) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein
Excerpt:
...we report a novel cholangiocarcinoma PDX model expressing an FGFR2-CCDC6 fusion protein and demonstrate preclinical antitumor activity of the nonspecific multikinase inhibitors ponatinib and dovitinib and the FGFR-specific inhibitor BGJ389 against this tumor.
DOI:
https://dx.doi.org/10.1016%2Fj.canlet.2016.05.017
